Neurosurgery notes/Pharmacology/Anti-inflammatory/Steroids in anti-inflammatory

Steroids in anti-inflammatory

View Details

Dexamethasone

Indications

  • Brain tumour
  • Post radiotherapy

Pros of dex vs other corticosteroids

  • A potent glucocorticoid with very little if any, mineralocorticoid activity
    • Dexamethasone relative lack of mineralocorticoid activity reduces the potential for fluid retention.
  • Dexamethasone may be associated with a lower risk of infection and cognitive impairment compared to other glucocorticoids.

Pharmacodynamic

  • Multiple mechanism of action
    • Suppressing the migration of neutrophils and decreasing lymphocyte colony proliferation
    • The capillary membrane becomes less permeable
      • Dexamethasone has been shown to
        • Upregulate Ang-1
          • A strong BBB-stabilizing factor
        • Downregulates VEGF
          • A strong permeabilizing factor, in astrocytes and pericytes.
          • VEGF is responsible for the loss of integrity of the blood-brain barrier in brain tumours.
            • Gliomas, meningiomas, and metastatic tumours all have upregulation of VEGF.
            • Mechanism of VEGF
              • VEGF secreted by
                • Tumour cells
                • Host stromal cells
              • VEGF binds to its receptors VEGFR1 and VEGFR2, which are located primarily on the surface of endothelial cells.
              • VEGF stimulates the formation of gaps in the endothelium → fluid leakage into the brain parenchyma → vasogenic oedema.
          • Tumor-related disruption in the blood-brain barrier resulting in vasogenic oedema is caused by local factors increasing the permeability of vessels (VEGF, glutamate, leukotrienes) and absence of normal tight endothelial junctions in tumour vessels as they grow in response to VEGF and bFGF.
        • Increase the clearance of peritumoral oedema
          • By facilitating the transport of fluid into the ventricular system, from which it is cleared by CSF bulk flow.
      • Reduction of intracranial pressure and improvement in neurologic symptoms usually begins within hours.
        • A decrease in capillary permeability (i.e. improvement in blood-brain barrier function) can be identified within 6 h
        • Changes of DWI MRI indicating decreased oedema are identifiable within 48-72 h.
        • However, adequate reduction in elevated ICP resulting from peritumoral oedema may take several days with glucocorticoid therapy alone.
    • Lysosomal membranes have increased stability.
    • There are higher concentrations of vitamin A compounds in the serum, prostaglandin, and some cytokines (interleukin-1, interleukin-12, interleukin-18, tumour necrosis factor, interferon-gamma, and granulocyte-macrophage colony-stimulating factor) become inhibited.
    • Increased surfactant levels and improved pulmonary circulation have also been shown with dexamethasone.
    • Dexamethasone is metabolized by the liver and excreted in the urine mainly.

Pharmacokinetics

  • Oral dexamethasone dose: between the dose range of 0.5 to 40 mg.
    • Most studies suggest splitting it to TDS or QDS
  • Absorption
    • Median time to peak concentrations (Tmax) is 1 hour (range: 0.5 to 4 hours).
    • A high-fat, high-calorie diet decreased C max by 23% of a single 20 mg dose of dexamethasone.
  • Distribution
    • 77% bound to human plasma proteins
  • Elimination
    • Terminal half-life of dexamethasone is 4 hours (18%)
    • Oral clearance is 15.7 L/hr following a single dose of dexamethasone.
  • Metabolism
    • Metabolized by CYP3A4.
  • Excretion
    • Renal excretion of dexamethasone is less than 10% of total body clearance.

CI

  • Systemic fungal infections,
  • Hypersensitivity to dexamethasone
  • Cerebral malaria.

Side effects

Organ system
Complication
Prevention (key points)
Treatment (key points)
Endocrine
Hyperglycemia
Counsel patients on diet and exercise.
Patients with type 1 diabetes (or with type 2 diabetes on insulin) who are receiving glucocorticoid therapy and whose fasting plasma glucose is below 13 mmol/L can be followed in the oncology clinic together with their primary care physician. If their fasting plasma glucose is greater than 13 mmol/L, they should be referred to an endocrinologist or diabetologist.
Muscular
Myopathy
Use lowest effective dexamethasone dose; encourage fitness, aerobic exercise, and weight training; avoid skin breakdown by minimizing repetitive shear forces on patient’s skin during all types of exercise.
Lower dose or switch medication might reduce extent of myopathy; consider switching from fluorinated to non‑fluorinated corticosteroid to reduce myopathy.
Skeletal
Osteoporosis, avascular necrosis
Encourage bone health: weight‑bearing exercise, calcium (diet + supplements) 1200 mg/day, vitamin D 800–2000 IU/day, fall‑prevention; for life expectancy >6 months, consider bisphosphonate at the outset for duration of glucocorticoid therapy in adults >50 years or on long‑term glucocorticoid therapy (>3 months).
Refer patients with complications to endocrinologist or rheumatologist; refer to orthopaedic surgeon for compression fractures.
Gastrointestinal
Peptic ulceration, bowel perforation
Use prophylactic proton‑pump inhibitors in patients with ulcer/gastrointestinal bleeding history or on NSAIDs, aspirin, or anticoagulants; consider H₂ blockers or PPIs as appropriate; use laxatives (PEG or lactulose) to prevent constipation and bowel perforation.
PPIs are drugs of choice for peptic ulcers including NSAID‑induced ulcers; lansoprazole, omeprazole, pantoprazole have similar efficacy at standard doses.
Psychiatric
Anxiety, irritability, insomnia, mania, psychosis, depression, seizures
For insomnia: lowest effective corticosteroid dose, avoid long daytime naps, regular sleep/rest schedule, avoid smoking/alcohol/caffeine before sleep, avoid vigorous exercise before bed, use relaxation strategies (meditation, warm baths and music).
Sedatives for insomnia such as zopiclone or temazepam; refer to mental health professionals, social worker or spiritual counsellor for moderate–severe distress; psychotherapy plus antidepressant ± anxiolytic for anxiety/mood disorder; for psychosis, an effort should be made to stop dexamethasone or to gradually reduce the dose. Neuroleptics and lithium might be considered in consultation with psychiatrist.
Infections
Pneumocystis jirovecii pneumonia (PJP), candidiasis
Consider prophylactic therapy with trimethoprim–sulfamethoxazole against PJP in brain‑cancer patients on prolonged corticosteroids.
Treat PJP infection with trimethoprim–sulfamethoxazole, trimethoprim plus dapsone, atovaquone suspension, clindamycin plus primaquine, or pentamidine. Oropharyngeal candidiasis should be treated with nystatin, fluconazole, or itraconazole.
Hematologic
Venous thromboembolism (VTE)
Routine antithrombotic prophylaxis not recommended; prophylaxis with low‑molecular‑weight heparin (such as dalteparin, enoxaparin, or tinzaparin), fondaparinux, unfractionated heparin, or warfarin may be appropriate for people who are judged to be at risk of venous thromboembolism after assessing their risk factors.
Low‑molecular‑weight heparin preferred for cancer patients with established VTE and for long‑term anticoagulation.
Cardiovascular
Hypertension, increased cardiovascular risk
No clear evidence for routine prevention and treatment of corticosteroid‑induced hypertension; monitor blood pressure, especially in first months of therapy; consider measures in patients with corticosteroid‑induced lipodystrophy.

Q&A

  • Which doses of steroids is unlikely to cause hypothalamic–pituitary–adrenal axis suppression?
    • Less than 40 mg of prednisone (or its equivalent) given in the morning for less than 1 week.
    • Axis suppression will certainly occur after 40 to 60 mg daily of hydrocortisone (or its equivalent) after 2 weeks.
    • After a month or more of steroids the axis may be depressed for almost one year.
  • What are the equivalent corticosteroid doses?
    • Steroid
      Dose
      Effect duration
      Dexamethasone
      0.75 mg
      24-72hr
      Methylprednisolone
      4 mg
      12-36hr
      Prednisone
      5 mg
      12-36hr
      Hydrocortisone
      20 mg
      8-12hr
      Cortisone
      25 mg
      Trial
      Loading dose
      Maintenance dose
      Duration
      CRASH12345
      2 g
      0.4 g/hr
      48 hours
      NASCIS 1136
      1000 mg bolus
      1000 mg daily
      10 days
      NASCIS 21578
      30 mg/kg
      5.4 mg/kg/hr
      23 hours
      NASCIS 31234
      No bolus
      5.4 mg/kg/hr
      48 hours